Chembio Diagnostics (CEMI) to Release Earnings on Thursday

Chembio Diagnostics (NASDAQ:CEMI – Get Rating) will be releasing its earnings data after the market closes on Thursday, August 4th. Persons interested in registering for the company’s earnings conference call can do so using this link.

Chembio Diagnostics (NASDAQ:CEMI – Get Rating) last issued its earnings results on Thursday, May 5th. The company reported ($0.29) earnings per share for the quarter. Chembio Diagnostics had a negative return on equity of 100.75% and a negative net margin of 65.95%. The firm had revenue of $18.82 million during the quarter. During the same quarter in the prior year, the firm posted ($0.22) earnings per share.

Chembio Diagnostics Stock Performance

Shares of CEMI stock opened at $0.69 on Thursday. The company has a debt-to-equity ratio of 0.64, a current ratio of 3.54 and a quick ratio of 2.67. Chembio Diagnostics has a fifty-two week low of $0.42 and a fifty-two week high of $3.78. The stock’s 50-day moving average is $0.70 and its two-hundred day moving average is $0.78. The firm has a market cap of $20.73 million, a P/E ratio of -0.47 and a beta of 1.69.

Wall Street Analyst Weigh In

Separately, StockNews.com began coverage on Chembio Diagnostics in a research report on Sunday. They issued a “sell” rating on the stock.

Institutional Trading of Chembio Diagnostics

An institutional investor recently bought a new position in Chembio Diagnostics stock. Bank of New York Mellon Corp purchased a new position in shares of Chembio Diagnostics, Inc. (NASDAQ:CEMI – Get Rating) in the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 124,750 shares of the company’s stock, valued at approximately $102,000. Bank of New York Mellon Corp owned approximately 0.41% of Chembio Diagnostics as of its most recent filing with the SEC. Institutional investors own 13.27% of the company’s stock.

Chembio Diagnostics Company Profile

(Get Rating)

Chembio Diagnostics, Inc, together with its subsidiaries, develops, manufactures, and commercializes point-of-care (POC) diagnostic tests that are used to detect or diagnose diseases. The company offers tests for COVID-19, HIV and Syphilis, and Zika virus. It also develops tests for malaria, dengue, chikungunya, Chagas, ebola, leishmaniasis, lassa, marburg, leptospirosis, rickettsia, and Burkholderia diseases.